加速器墙

AstraZeneca’s response to the COVID-19 (novel coronavirus) outbreak is consistent with our values to follow the science, put patients first and do the right thing. Our priorities are to ensure the continued supply of our medicines to patients, and to safeguard the health and wellbeing of all our employees and communities.

Our support for the COVID-19 response in the UK

加速器墙

Visit the COVID-19 Global information hub

加速器墙

Bringing science to patients, creating value for Britain

加速器墙

6,500 employees at 5 sites across the UK (as of May 2023)

9% of total pharmaceutical sector employment with a further 39,000 UK jobs supported including Research and Development, Manufacturing, Supply, Sales and Marketing

加速器墙

At the centre of what we do

Our purpose is to push the boundaries of science to deliver lifechanging medicines for patients. We partner with the scientific community to discover and develop these innovative treatments. We work with the NHS in areas such as patient pathway re-design, data, precision medicine and genomics. We are dedicated to collaborating with the NHS to make sure patients have access to the cutting-edge treatments they need. By using precision medicine in ~90% of our clinical pipeline, we aim to tailor new and existing treatments to the needs of individual patients through diagnostic tests.

加速器墙

In the future of UK science

We are investing over £500m in our future global HQ and strategic R&D centre in Cambridge. We have also invested £220m in new manufacturing, warehousing and infrastructure improvements at our Macclesfield campus between 2015-18, representing a spend of over £1m per week. This is the largest medicines manufacturing site in the UK.

VVPM ID: GB-21240 Date of Prep: April 2023